CAMP Phase I SYNGAP1 trial authorized to start in Q4
CAMP’s upcoming Phase I SYNGAP1 trial in multiple countries is authorized to begin in Q4. The multi-cohort study will use preclinical and natural history data, with endpoints across cognitive, motor and seizure domains.
SYNGAP1, a rare neurological disorder with no approved therapies, will be the focus of an upcoming phase I trial authorized in multiple countries and scheduled to begin in Q4. The multi-cohort study will use preclinical and natural history data and will assess endpoints in cognitive, motor and seizure domains.